|
NPPA makes price revision on pharma products based on commerce ministry’s annual change in WPI
|
|
Shardul Nautiyal, Mumbai
March 23 , 2021
|
|
|
The National Pharmaceutical Pricing Authority (NPPA) has made price revision on pharma products based on Union commerce ministry’s annual change in WPI at 0.53638% during the calendar year 2020 over the corresponding period in 2019.
The WPI data is available on the website of the office of the economic advisor, Department for Promotion of Industry and Internal Trade (DIPP). The same has also been brought to the notice of all concerned stakeholders and manufacturers for further action as per the provisions of DPCO-2013.
Based on this change in WPI, NPPA made price revision based on WPI for inhaler of Glenmark Pharmaceuticals Ltd as per para 16 of DPCO, 2013 through an order dated December 18, 2019, for the phrase “The price of the digital dose counter as specified would remain fixed irrespective of the subsequent change in the ceiling price of the formulation (a) budesonide 100mcg+ formeterol 6mcg per dose inhaler 120 MDI (b) budesonide 200mcg+ formeterol 6mcg per dose inhaler 120 MDI and (c) budesonide 400mcg+ formeterol 6mcg per dose Inhaler 120 MDI of Glenmark Pharmaceuticals Ltd having digital dose counter.” mentioned in Note (e) it is to be read as follows “The price revision based on WPI as per para 16 of DPCO, 2013 would be applicable on the price of the digital dose counter as specified from the next year”.
All other notes and contents mentioned in the S.O. 4539(E) dated December 18, 2019 shall remain the same and are applicable.
Besides the above, NPPA also made price revision based on WPI for inhaler of Cipla Ltd with reference to the S.O. 4538(E) dated December 18, 2019, for the phrase “The price of the synchrobreathe inhaler device as specified would remain fixed irrespective of the subsequent change in the ceiling price of the formulation (a) budesonide 200mcg+ formeterol 6mcg per dose inhaler 120 MDI and (b) budesonide 400mcg+ formeterol 6mcg per dose inhaler 120 MDI of Cipla Ltd.” mentioned in Note (e) it is to be read as follows “The price revision based on WPI as per para 16 of DPCO, 2013 would be applicable on the price of the synchrobreathe inhaler device as specified from the next year”.
All other notes and contents mentioned in the S.O. 4538(E) dated December 18, 2019 shall remain the same and are applicable.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|